Published in Medical Letter on the CDC and FDA, October 31st, 2004
The 2-year award for approximately $750,000 will be used to enhance core components of SimPheny, the company's flagship software platform. These enhancements will expand SimPheny's ability to support collaborative research efforts at leading academic and commercial institutions focused on metabolic research.
"We are very pleased that the DOE has recognized SimPheny as a valuable part of the computational infrastructure for systems biology and has elected to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.